Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on July 10, 2019, with the earliest event reported on July 10, 2019. The company is a Delaware corporation listed on the Nasdaq Global Market under the symbol LPTX. The filing primarily discloses the entry into material definitive agreements regarding equity financing with Lincoln Park Capital Fund, LLC.
Key Financial Metrics and Agreements
- Equity Commitment Facility: Entered into a Commitment Purchase Agreement allowing the sale of up to $20,000,000 of common stock to Lincoln Park over a 24-month period.
- Immediate Registered Offering: On July 11, 2019, the company sold 571,429 shares at $1.75 per share, generating aggregate proceeds of approximately $1,000,000.
- Commitment Shares: Issued 330,000 shares of common stock to Lincoln Park as consideration for the commitment. No cash proceeds were received for these shares.
- Usage of Proceeds: Expected to be used for working capital and general corporate purposes.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. It is a current report on specific events.
Material Changes and Terms
- Ownership Limits: Sales under the agreement are capped to prevent Lincoln Park from beneficially owning more than 9.99% of the outstanding common stock. Additionally, total issuance cannot exceed 19.99% of shares outstanding prior to signing without shareholder approval.
- Purchase Mechanics: The company may direct purchases of up to 50,000 shares per business day (subject to price thresholds), with a maximum of $1,500,000 in proceeds per purchase date. Accelerated purchases are permitted if stock prices meet certain thresholds.
- Pricing: Purchase prices are based on market prices at the time of sale. There is no upper limit on the price per share Lincoln Park must pay.
- Restrictions: Lincoln Park is prohibited from short selling or hedging the common stock. The company is prohibited from entering into "Variable Rate Transactions."
Outlook, Risks, and Management Commentary
- Discretionary Funding: Actual sales under the commitment depend on market conditions, trading prices, and management's determination of funding needs. The company may terminate the agreement at any time without penalty.
- Regulatory Status: The commitment shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The registered offering shares were sold pursuant to an effective shelf registration statement (Form S-3).
- Emerging Growth Company: The registrant is classified as an emerging growth company.
Investor Verification Checklist
- Verify the current share count to calculate the dilution impact of the 330,000 commitment shares and the 571,429 registered shares.
- Review the full text of the Commitment Purchase Agreement (Exhibit 10.2) for specific price calculation formulas and acceleration triggers.
- Confirm the company's cash runway and working capital needs to assess the likelihood of utilizing the full $20 million facility.
- Check subsequent filings to monitor the frequency and volume of shares sold under the facility.
- Verify the status of the 19.99% issuance cap relative to the current outstanding share count.